Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case report.
Authors:
- 15 July 2014
- journal article
- case report
- Vol. 7 (8) , 5295-301
Abstract
Uterine carcinosarcoma (malignant mixed Müllerian tumor, MMMT) is a rare aggressive malignant tumor, which demonstrates both malignant epithelial (carcinoma) and mesenchymal (sarcoma) components. Synchronous uterine carcinosarcoma and contralateral breast cancer in patient received tamoxifen treatment had not been reported. We present a case of uterine carcinosarcoma co-occurrenced with contralateral breast cancer in a 56-year-old nulliparous, obese breast cancer patient, who had been treated with tamoxifen for 5 years. The patient presented with palpable pelvic mass and vaginal bleeding. Histopathological evidence revealed that the tumor was comprised of an admixture of malignant epithelial and mesenchymal components. The epithelial component was endometrioid type adenocarcinoma, while sarcomatous component had heterologous elements including fusiform cell sarcoma and a prominent component of cartilage. The infiltrating ductal carcinoma has been diagnosed on her right breast. The patient died of disease 8 months after diagnosis. Postmenopausal patients, with adjuvant tamoxifen treatment for breast cancer, are at increased risk for the development of uterine carcinosarcoma and less benefit for contralateral breast cancer.Keywords
This publication has 23 references indexed in Scilit:
- Why are reproductive cancers more common in nulliparous women?Reproductive BioMedicine Online, 2013
- A multi-institutional cohort study of adjuvant therapy in stage I–II uterine carcinosarcomaGynecologic Oncology, 2012
- Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in ManagementObstetrics and Gynecology International, 2011
- Joint effects of nulliparity and other breast cancer risk factorsBritish Journal of Cancer, 2011
- Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor–Specific Subtypes of Contralateral Breast CancerCancer Research, 2009
- Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Fatty liver and transaminase changes with adjuvant tamoxifen therapyAnti-Cancer Drugs, 2006
- Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literatureInternational Journal of Gynecological Cancer, 2002
- Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.International Journal of Oncology, 2000
- Epidemiology of contralateral breast cancer.1999